tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CRISM Therapeutics Wins Prestigious Award for ChemoSeed Research

Story Highlights
CRISM Therapeutics Wins Prestigious Award for ChemoSeed Research

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amur Minerals ( (GB:CRTX) ) has shared an update.

CRISM Therapeutics Corporation has been awarded the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society for its groundbreaking research on ChemoSeed, a localized chemotherapy delivery technology. This recognition underscores the potential of ChemoSeed to revolutionize treatment for glioblastoma by providing targeted, sustained therapeutic action at the tumor site, enhancing efficacy while minimizing systemic toxicity. The award highlights the innovative nature of CRISM’s platform and its promise to improve cancer treatment outcomes.

More about Amur Minerals

CRISM Therapeutics Corporation is a UK-based innovative drug delivery company focused on enhancing cancer treatment for solid tumors through localized chemotherapy drug delivery. Their lead product, ChemoSeed, is designed to be implanted directly into tumors, particularly glioblastoma, to bypass the blood-brain barrier and deliver therapeutic concentrations of chemotherapy drugs effectively.

Average Trading Volume: 62,767

Technical Sentiment Signal: Strong Buy

Current Market Cap: £1.7M

See more insights into CRTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1